Fusion protein of thymic stromal lymphopoietin-immunoglobulin inhibits the in vitro activation on dendritic cells by TSLP

ZHANG Fang,SHI Yi,LI Zi-ling,HU Bo,SONG Yong
2010-01-01
Abstract:Thymic stromal lymphopoietin(TSLP) can activate dendritic cells(DC) through the combination with TSLP receptor(TSLPR) on DC surface,resulting in Th1/Th2 imbalance in asthma.The aim of this study is to find out the feasibility of the soluble TSLPR receptor(mTSLPR-Ig),constituted by the fusion protein of the extracellular segment of mouse TSLPR and Fc segment of mouse immunoglobulin,to inhibit the activation of DC by TSLP in vitro.The murine myeloid DCs were isolated and identified,and then mTSLPR-IG was added to the culture system,in which DCs were effected byTSLP(TSLP-DCs).The influence of mTSLP-Ig on the expression of surface co-stimulatory molecules CD80,CD86 and CD40 was analyzed by FCM.In addition.the impact of the added mTSLPR-Ig fusion protein on the proliferative activity of CD4+ cells was analyzed by FCM and the changes of cytokine,such as IL-4,IL-5,IFN-γ and IL-10,in the cultural supernatants were detected by ELISA.It was demonstrated that expressions of surface co-stimulatory molecules CD80,CD86 and CD40 were significantly inhibited by fusion protein mTSLPR-Ig and mTSLPR-Ig also could inhibit significantly the proliferative activity of the antigen-specific T cells induced by this fusion protein,and promote the secretion of IL-10 and IFN-γ in the cultural supernatants,but inhibit the expression levels of IL-4 and IL-5.From these observation,it is evident that fusion protein mTSLPR-Ig can inhibit the activation of the TSLP-DCs,resulting Th2 biasis,and it is expected that this protein may play some role in the treatment of the TSLP-related disorders,such as asthma or allergic dermatitis.
What problem does this paper attempt to address?